[1]
Zucchella, C.; Sinforiani, E.; Tamburin, S.; Federico, A.; Mantovani, E.; Bernini, S.; Casale, R.; Bartolo, M. The multidisciplinary approach to alzheimer’s disease and dementia. a narrative review of non-pharmacological treatment. Front. Neurol., 2018, 9, 1058.
[3]
Uddin, M.S.; Al Mamun, A.; Kabir, M.T.; Ashraf, G.M.; Bin-Jumah, M.N.; Abdel-Daim, M.M. Multi-target drug candidates for multifactorial alzheimer’s disease: AChE and NMDAR as molecular targets. Mol. Neurobiol., 2021, 58(1), 281-303.
[4]
Jiang, J.; Jiang, H. Efficacy and adverse effects of memantine treatment for Alzheimer’s disease from randomized controlled trials. Neurol. Sci., 2015, 36(9), 1633-1641.
[5]
Souchet, B.; Audrain, M.; Billard, J.M.; Dairou, J.; Fol, R.; Orefice, N.S.; Tada, S.; Gu, Y.; Dufayet-Chaffaud, G.; Limanton, E.; Carreaux, F.; Bazureau, J.P.; Alves, S.; Meijer, L.; Janel, N.; Braudeau, J.; Cartier, N. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice. Acta Neuropathol. Commun., 2019, 7(1), 46.
[6]
Branca, C.; Shaw, D.M.; Belfiore, R.; Gokhale, V.; Shaw, A.Y.; Foley, C.; Smith, B.; Hulme, C.; Dunckley, T.; Meechoovet, B.; Caccamo, A.; Oddo, S. Dyrk1 inhibition improves Alzheimer’s disease-like pathology. Aging Cell, 2017, 16(5), 1146-1154.
[7]
de Souza, M.M.; Cenci, A.R.; Teixeira, K.F.; Machado, V.; Schuler, M.C.G.M.; Gonçalves, A.E.; Dalmagro, A.P.; Cazarin, C.A.; Ferreira, L.L.G.; Oliveira, A.S. de; Andricopulo, A.D. DYRK1A inhibitors and perspectives for the treatment of Alzheimer’s disease. Curr. Med. Chem., 2023, 30, 669-688.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
